We are live on
!
Find out more
Neurocrine Biosciences
NBIX
NBIX
649 hedge funds and large institutions have $13.6B invested in Neurocrine Biosciences in 2025 Q3 according to their latest regulatory filings, with 121 funds opening new positions, 220 increasing their positions, 219 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
142% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 50
11% more funds holding
Funds holding: 585 → 649 (+64)
10% more capital invested
Capital invested by funds: $12.4B → $13.6B (+$1.19B)
0% more repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 219
1.93% less ownership
Funds ownership: 99.95% → 98.01% (-1.9%)
31% less funds holding in top 10
Funds holding in top 10: 16 → 11 (-5)
51% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $67.7M
Holders
649
Holders Change
+64
Holders Change %
+10.94%
% of All Funds
8.52%
Holding in Top 10
11
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-31.25%
% of All Funds
0.14%
New
121
Increased
220
Reduced
219
Closed
50
Calls
$33.1M
Puts
$67.7M
Net Calls
-$34.6M
Net Calls Change
-$45.3M
Top Buyers
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$171M |
| 2 |
JP Morgan Chase
New York
|
+$63.5M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$62.1M |
| 4 |
Two Sigma Investments
New York
|
+$47.1M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$38.8M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$170M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$84.3M |
| 3 |
Axa
Paris,
France
|
-$43M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$42.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$38M |
